Kinrix

Kinrix ⁹ vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous dose of any
  • diphtheria toxoid-, tetanus toxoid-, pertussis- or poliovirus-containing
  • vaccine;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Severe allergic reaction to any component of Kinrix, including neomycin and polymyxin B (antibiotics);
  • The tip caps of prefilled Kinrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Kinrix should be carefully considered prior to vaccination. 

Kinrix is FDA approved for use in children between the ages of four and six years. Kinrix should not be administered to children younger than four years or older than six years of age.